Circio

Actithera is a company specializing in developing radioligand therapies through the application of medicinal chemistry knowledge and innovative molecular design techniques. Their approach involves creating new RLTs using strategies like covalent targeting and an isotope-neutral mindset to produce therapies with enhanced efficacy and broader therapeutic benefits.

NoMy is a company focused on creating sustainable and scalable solutions for alternative proteins by harnessing the power of mycelium, the fungal biomass.

Hofseth BioCare's key goal is to offer high benefit added biomarine elements for human applications. Through inventive creation innovation and coordinated factors, they safeguard the nature of protein, calcium and oil extricated from fish. This innovation is exclusive to their organization.

Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies. Our goal is to revolutionize cancer therapy by developing TCR based therapies with the potential to treat a wide range of cancer types and patients. Zelluna’s core asset is a wide range of TCRs isolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav Gaudernack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently the company has several TCRs in different stages of development. We are a member of Oslo Cancer Cluster (Norwegian Centre of Expertise), a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals. Zelluna is located at the Oslo Cancer Cluster Innovation Park, next to the Norwegian Radium Hospital/Oslo University Hospital, the Department for Cellular Therapy and one of Europe’s largest academic certified GMP facilities for cellular products.

Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer therapeutics.

Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns.

Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.

NEXT offers secure and user-friendly fingerprint sensor technology for verification purposes in various markets such as smart card, government ID, access control, and notebook. The company's unique NEXT Active Thermal™ principle permits the creation of high-quality fingerprint sensors in both rigid and flexible formats. NEXT Biometrics Group ASA is based in Oslo and has sales, support, and development centers in Seattle, Silicon Valley, Taipei, Prague, and Shanghai.

IDEX, a biometrics software and fingerprint authentication company based in Oslo, Norway, was established in 1996. They specialize in providing fingerprint sensor technology and biometric software for various security solutions, including identity cards, banking cards, and smart cards. IDEX is known for their patented SmartFinger® Film fingerprint sensor technology and software algorithms. Their products are distributed through partnerships with global companies like Ionics EMS, Faraday Technology, and Validus Technologies Corporation. The SmartFinger® Film sensors are thin, flexible, and based on advanced polymer process technologies, making them suitable for use in products such as finger recognition solutions for devices like Apple iPhone and iPad.

We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who get ENT and allergy treatments. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, is a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if authorized, chronic rhinosinusitis without nasal polyps. It uses our exclusive Exhalation Delivery System (EDS) (also known as chronic sinusitis) The US Food and Drug Administration (FDA) approved XHANCE in September 2017 for the treatment of nasal polyps in individuals who were 18 years of age or older. In April 2018, XHANCE became readily accessible through commercial channels.

Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These include novel therapeutic candidates that fulfill unmet clinical needs across a spectrum of diseases.

CardioMech, a developer of therapeutic devices for structural heart disease, offers a transcatheter solution for placing artificial chords in the mitral valve. These devices provide an alternative to cardiac surgery and allow surgeons to explore new therapeutic options for heart diseases. The technology aims to treat patients suffering from severe, symptomatic, degenerative mitral regurgitation (DMR) caused by prolapse or flail. Established in 2015, CardioMech is based in Trondheim, Norway.